Back to Browse Journals » Journal of Pain Research » Volume 3

Milnacipran for the management of fibromyalgia syndrome

Authors Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, et al

Published Date March 2010 Volume 2010:3 Pages 15—24

DOI http://dx.doi.org/10.2147/JPR.S7883

Published 1 March 2010

Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, Chad S Boomershine

Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA

Abstract: Fibromyalgia syndrome (FMS) is a widespread pain condition associated with fatigue, cognitive dysfunction, sleep disturbance, depression, anxiety, and stiffness. Milnacipran is one of three medications currently approved by the Food and Drug Administration in the United States for the management of adult FMS patients. This review is the second in a three-part series reviewing each of the approved FMS drugs and serves as a primer on the use of milnacipran in FMS treatment including information on pharmacology, pharmacokinetics, safety and tolerability. Milnacipran is a mixed serotonin and norepinephrine reuptake inhibitor thought to improve FMS symptoms by increasing neurotransmitter levels in descending central nervous system inhibitory pathways. Milnacipran has proven efficacy in managing global FMS symptoms and pain as well as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. Due to its antidepressant activity, milnacipran can also be beneficial to FMS patients with coexisting depression. However, side effects can limit milnacipran tolerability in FMS patients due to its association with headache, nausea, tachycardia, hyper- and hypotension, and increased risk for bleeding and suicidality in at-risk patients. Tolerability can be maximized by starting at low dose and slowly up-titrating if needed. As with all medications used in FMS management, milnacipran works best when used as part of an individualized treatment regimen that includes resistance and aerobic exercise, patient education and behavioral therapies.
Keywords: fibromyalgia, milnacipran, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Duloxetine in the management of diabetic peripheral neuropathic pain

Ormseth MJ, Scholz BA, Boomershine CS

Patient Preference and Adherence 2011, 5:343-356

Published Date: 19 July 2011

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009

Pregabalin for the management of fibromyalgia syndrome

Chad S Boomershine

Journal of Pain Research 2010, 3:81-88

Published Date: 22 June 2010

Readers of this article also read:

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009

Pregabalin for the management of fibromyalgia syndrome

Chad S Boomershine

Journal of Pain Research 2010, 3:81-88

Published Date: 22 June 2010

Acute pain management in children

Susan T Verghese, Raafat S Hannallah

Journal of Pain Research 2010, 3:105-123

Published Date: 15 July 2010

Anesthesiologists’ perception of patients’ anxiety under regional anesthesia

Hatem A Jlala, Nigel M Bedforth, Jonathan G Hardman

Local and Regional Anesthesia 2010, 3:65-71

Published Date: 12 August 2010

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

Xianchen Liu, Yi Chen, Douglas E Faries, et al

ClinicoEconomics and Outcomes Research 2011, 3:63-72

Published Date: 15 March 2011

Predictors of duloxetine adherence and persistence in patients with fibromyalgia

Cui Z, Zhao Y, Novick D, Faries D

Journal of Pain Research 2012, 5:193-201

Published Date: 22 June 2012